Jun 08, 2020
Neurelis Announces Rapid and Broad Payer Coverage of the Company's Flagship Product, VALTOCO® (Diazepam Nasal Spray)
May 04, 2020
Neurelis Announces That Intravail® Licensee, ARS Pharmaceuticals' Intranasal Epinephrine Product, Demonstrates Bioequivalent Exposure To Epinephrine Injectors
Oct 16, 2019
New Jersey's Leading Drug and Alcohol Detox Program To Open A Freehold, New Jersey Location
Oct 15, 2019
Diazepam Market To Reach USD 1.27 Billion By 2026 | Reports And Data
May 08, 2019
Why Drug Overdoses in New Jersey Are Likely to Head South
Apr 22, 2019
Anti-depressant Prescriptions Associated with Increased Total Workers' Compensation Claims Cost, Delayed Return to Work
Feb 25, 2019
Benzodiazepine Drugs Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2026
Feb 20, 2019
Biohaven Enrolls First Patient In Phase 3 Generalized Anxiety Disorder (GAD) Trial Of Troriluzole
Dec 18, 2018
Hollywood Mainstreaming Addiction Should Reduce Stigma
Dec 13, 2018
Drug and Alcohol Relapse Rates Spike 150% during the Holidays
Dec 03, 2018
Aquestive Therapeutics Announces Late-Breaking Findings of its Investigational Diazepam Buccal Film (DBF) Formulation in Adults with Epilepsy
Oct 23, 2018
Are Anti-Anxiety Meds the Next Opioid Crisis? "BENZO FREE," a New Book by D E Foster, Reveals the Facts and Intimate Reality of this Developing Epidemic
May 24, 2018
Commencement of BNC210 Phase 2 Clinical Trial for the Treatment of Agitation
Feb 21, 2018
Rebound Pharmacy Withdrawal - Danish Startup App Brings Awareness on Medicine Discontinuation as an Underestimated Challenge
Feb 20, 2018
Antidepressant Drugs Market Global Analysis By Drugs Class, By Sales Channel, By Region, By Country: Opportunities And Forecasts 2018 to 2023
Jan 25, 2018
CCHR: Another Celebrity Lost to Benzodiazepines and Opioids Mix
Jan 02, 2018
New Drug Testing Approach a Game-Changer for Benzodiazepine Abuse
Nov 07, 2017
Neurelis Expands Worldwide Patent Portfolio With Latest Issuance In Japan
Nov 06, 2017
UCB's VIMPAT® (lacosamide) now approved by FDA to treat partial-onset seizures in pediatric epilepsy patients
Oct 17, 2017
Over 130,000 US Toddlers and Children Aged 0-5 Are Prescribed Addictive 'Anti-Anxiety' Drugs